Pharma News

WuXi AppTec, a leading pharmaceutical company, has announced its impressive financial results for the year 2023. With remarkable growth in revenue and net profit, the company has achieved a significant milestone in its history.

Peptides have emerged as a revolutionary force in the field of pharmaceuticals, consistently gaining recognition in clinical settings and experiencing exponential market growth.

BIO-THERA and SteinCares, two prominent biotech companies, have recently entered into a significant licensing and commercialization agreement worth $6 million.

Mabwell Biotechnology unveiled groundbreaking clinical data on their targeted therapy, Nectin-4 ADC, for the treatment of cervical cancer.

In a recent strategic partnership, CanSino Biologics (Shanghai) Biotechnology Co., Ltd. and Shanghai AsymBio Biotechnology Co., Ltd. have joined forces to focus on the advancement of mRNA technology.

"TROP 2 ADC" has achieved formal acceptance by the China Drug Administration (CDE) for the treatment of advanced breast cancer.

Novartis, a leading pharmaceutical company, recently announced its acquisition of IFM Due, a subsidiary of IFM Therapeutics, in a deal worth $835 million.

In just two years, Apogee has achieved a staggering market value of $4 billion. This remarkable success story revolves around a meticulously planned "biotech experiment."

Madrigal Pharmaceuticals announced on their official website that the FDA has granted accelerated approval for Rezdiffra (resmetirom) in combination with diet and exercise to treat non-cirrhotic non-alcoholic steatohepatitis (NASH) patients.

In an exciting development, Hansoh Pharma and Pumis have expanded their strategic partnership.

In the fast-paced world of pharmaceuticals, breakthrough innovations and game-changing products often grab headlines.

The pharmaceutical industry is currently experiencing significant workforce reductions, with 36 prominent companies implementing measures to downsize their staff.

In a recent Capital Markets Day event held by Novonordisk, the pharmaceutical company unveiled encouraging clinical Phase I data for their novel obesity treatment drug, amycretin.

Merck, a leading pharmaceutical company, has recently announced a groundbreaking collaboration that could revolutionize the field of cancer therapeutics.

Bayer, a leading pharmaceutical company, has recently unveiled its groundbreaking medication, Acoramidis, aimed at revolutionizing the treatment of transthyretin amyloid cardiomyopathy (ATTR CM).

China has long been recognized as a global manufacturing powerhouse, with "Made in China" becoming synonymous with quality in various industries.

EGFR-TKIs (epidermal growth factor receptor-tyrosine kinase inhibitors) have revolutionized the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations.

Laekna Therapeutics revealed the acceptance of its clinical trial application for a novel weight-loss drug, LAE102, by China's Center for Drug Evaluation (CDE).

In a challenging turn of events, KronosBio, a prominent biotech company listed on NASDAQ, has witnessed a staggering 95% decline in its market value.

In the era of groundbreaking medical advancements such as ADCs, oligonucleotides, and gene editing, a new form of therapy is emerging as the next frontier in medicine.